Skip to content

Overview

Intellectual Property Law in Canada

Intellectual property in Canada is protected by federal statutes, the common law and contracts, and enforced mainly in the Federal Court. This guide summarizes patents and the 2026 Supreme Court ruling on medical treatment methods, trademarks, copyright, trade secrets and industrial designs, litigation and remedies, and how to build an IP strategy for the Canadian market.

11 min read Updated
ENFR

Key takeaways

  • Canadian patents last 20 years from filing, with additional term for CIPO delays on applications from December 2020.
  • Pharmascience v. Janssen, 2026 SCC 26, confirms that methods of medical treatment are not patentable.
  • Trademark registrations last 10 years and are renewable; non-use can be challenged after three years.
  • Copyright generally lasts for the author's life plus 70 years; moral rights can be waived but not assigned.
  • Fraudulently obtaining or disclosing a trade secret is a Criminal Code offence carrying up to 14 years.

Intellectual property in Canada: an overview

Intellectual property in Canada is governed mainly by federal statutes: the Patent Act, the Trademarks Act, the Copyright Act, the Industrial Design Act and the Plant Breeders' Rights Act, among others. The Canadian Intellectual Property Office (CIPO), part of Innovation, Science and Economic Development Canada, examines and registers patents, trademarks and industrial designs and records copyright registrations. Trade secrets and confidential information are protected mainly by the common law, the Civil Code of Québec and contract, with a Criminal Code offence for the most serious misappropriation. Enforcement takes place in the Federal Court, which has jurisdiction across Canada, and in the provincial superior courts.

Patent drawings, trademark logos and code on a desk representing intellectual property protection in Canada
Patents, trademarks, copyright and trade secrets each protect different aspects of a business's intellectual property in Canada.

For businesses, the core intellectual property questions are practical: what can be protected and how, who owns what employees and contractors create, how to clear new products and brands before launch, how to license and commercialize rights, and how to enforce them or defend against claims. Canadian law broadly follows international norms through treaties such as the Paris Convention, the Patent Cooperation Treaty, the Madrid Protocol and the Berne Convention, but there are important local rules on patentable subject matter, trademark use, moral rights, pharmaceutical patents and bilingual requirements in Quebec.

This guide summarizes each area of our intellectual property practice and links to detailed pages on patents, trademarks and brands, copyright and trade secrets and IP litigation.

Patents

A Canadian patent gives its owner the exclusive right to make, use and sell the claimed invention in Canada. For applications filed on or after 1 October 1989, the term is 20 years from the filing date (s. 44 of the Patent Act), subject to maintenance fees. An invention must be new, useful and non-obvious, and fall within patentable subject matter. Canada operates a first-to-file system, with a one-year grace period for disclosures by the applicant or someone who obtained the information from the applicant.

Two recent developments matter for patentees. First, for applications filed on or after 1 December 2020, s. 46.1 provides for an additional term to compensate for unreasonable delays by CIPO in issuing a patent, where the patent issues after the later of five years from filing and three years from the request for examination, and the patentee applies within the prescribed time. Second, in Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, decided on 17 July 2026, the Supreme Court of Canada confirmed that methods of medical treatment are not patentable in Canada, which affects claim drafting for pharmaceutical and medical technology inventions.

The pharmaceutical sector has its own framework, including the Patented Medicines (Notice of Compliance) Regulations, which link generic and biosimilar drug approvals to patent litigation, and certificates of supplementary protection that can extend protection for eligible drug patents. Software and AI-related inventions can be patented in Canada where the claimed invention is more than an abstract idea or a mere computer program, and CIPO examination practice and recent case law address where that line falls. See our patents page and our insight on software patents and AI inventions.

Trademarks and brands

A registered trademark gives its owner the exclusive right to use the mark throughout Canada in association with the registered goods and services. Since 2019, Canada no longer requires use before registration and has joined the Madrid Protocol, allowing international applications to designate Canada. Registrations last for an initial period of 10 years and are renewable for further 10-year periods (s. 46 of the Trademarks Act).

Use still matters. Three years after registration, any person can ask the Registrar to require the owner to show use of the mark in Canada in the preceding three years, and registrations that cannot be supported by use may be expunged (s. 45).

Oppositions allow third parties to challenge applications after advertisement, and bad faith is a ground of opposition and invalidity. Unregistered marks can be protected through passing off. In Quebec, the Charter of the French Language affects how trademarks are displayed on products and signage, with rules on French-language descriptive and generic terms that brand owners should review. See our trademarks and brands page and insights on section 45 non-use proceedings and commercial signage and trademarks in Quebec.

Copyright

Copyright arises automatically in original literary, dramatic, musical and artistic works, including software, and in performances, sound recordings and communication signals. The general term is the life of the author, the remainder of the calendar year of death and 70 years after that (s. 6 of the Copyright Act).

Registration is optional but provides evidentiary benefits. An employer owns copyright in works made by an employee in the course of employment, absent an agreement to the contrary (s. 13(3)), but contractors keep copyright unless they assign it in writing. Authors have moral rights of integrity and attribution, which cannot be assigned but may be waived in whole or in part (s. 14.1(2)).

Fair dealing for research, private study, education, parody or satire does not infringe copyright (s. 29), and further fair dealing purposes include criticism, review and news reporting with attribution; whether a dealing is fair is assessed case by case. Canada has not legislated specifically on AI training or AI-generated works; see our insight on AI training data and copyright risk.

Trade secrets

Confidential business information is protected through actions for breach of confidence, breach of contract and, in Quebec, the Civil Code. Since 2020, the Criminal Code has made it an offence to obtain, communicate or make available a trade secret knowingly by deceit, falsehood or other fraudulent means, punishable by up to 14 years' imprisonment on indictment (s. 391 of the Criminal Code). Practical protection depends on confidentiality agreements, access controls and careful management of departing employees; see our insight on departing employees and trade secrets.

Industrial designs

Registered industrial designs protect the visual features of shape, configuration, pattern or ornament of a finished article. The exclusive right ends on the later of 10 years after registration and 15 years after the filing date (s. 10 of the Industrial Design Act), subject to maintenance fees. See our insight on industrial design protection.

RightWhat it protectsTermRegistration
PatentNew, useful and non-obvious inventions20 years from filing (s. 44), plus possible additional termRequired (CIPO)
TrademarkSigns distinguishing goods or services10 years, renewable indefinitely (s. 46)Optional but recommended; passing off protects unregistered marks
CopyrightOriginal works, including softwareLife of the author plus 70 years (s. 6)Automatic; registration optional
Industrial designVisual features of finished articlesLater of 10 years from registration and 15 years from filing (s. 10)Required (CIPO)
Trade secretConfidential business informationAs long as confidentiality is maintainedNone; protected by contract, equity and Criminal Code s. 391
Practical point

Fix ownership at the start. Many disputes in Canada arise because contractors, founders or development partners created key assets without written assignments and moral rights waivers. A short review of employment, contractor and collaboration agreements before investment or sale is far cheaper than repairing ownership gaps under deal pressure.

IP litigation and enforcement

The Federal Court has jurisdiction over patents, trademarks, copyright and industrial designs throughout Canada, and only it can invalidate a patent or expunge a registration with effect against everyone; provincial superior courts can also hear infringement claims, especially where contractual or other provincial claims are involved. Remedies include injunctions, damages or an accounting of the infringer's profits, delivery up and, for copyright, statutory damages for commercial infringement of between CAD 500 and CAD 20,000 per work, in the court's discretion (s. 38.1 of the Copyright Act). Interlocutory injunctions are available but require a strong showing of irreparable harm.

Pharmaceutical patent litigation under the PM(NOC) Regulations is a specialized and high-volume area, with actions that can delay generic market entry while infringement and validity are decided. Border measures allow owners of registered trademarks and copyright to request assistance from the Canada Border Services Agency against counterfeit and pirated imports. See our IP litigation page and our insight on anti-counterfeiting and border measures.

Life sciences intellectual property

Pharmaceutical, biologic and medical device companies face a distinct intellectual property environment in Canada. Patent protection interacts with regulatory approval: the Patented Medicines (Notice of Compliance) Regulations allow innovators to list patents against approved drugs and bring infringement actions when a generic or biosimilar manufacturer seeks approval by reference to the innovator's product, and certificates of supplementary protection can add a period of protection for eligible patents on new medicinal ingredients. Data protection for innovative drugs, under the Food and Drug Regulations, provides a further period of exclusivity independent of patents.

Pricing is also regulated through the patent system. The Patented Medicine Prices Review Board reviews the prices of patented medicines sold in Canada to ensure they are not excessive, and its guidelines have changed several times in recent years. Our insights on PM(NOC) actions and PMPRB guidelines and drug pricing explain these regimes, and the 2026 Supreme Court decision on methods of medical treatment described above affects how claims to new uses and dosing regimens are framed; see our insight on medical use and dosing regimen patents.

Licensing, commercialization and competition law

Most IP creates value through licensing, distribution, franchising, joint development or sale. Canadian licences should define the licensed rights and territory precisely, address exclusivity and sublicensing, allocate ownership of improvements, set quality control standards for trademarks, deal with prosecution and enforcement of the licensed rights, and provide for royalties, audits, termination and post-termination use. Quality control is particularly important for trademarks, because use by a licensee benefits the owner only where the owner controls the character or quality of the goods or services.

Competition law sets limits. The exercise of intellectual property rights on its own is generally not anti-competitive, but licensing arrangements that go beyond the scope of the right, such as agreements between competitors to fix prices or allocate markets, settlements that delay generic entry on anti-competitive terms, or conduct by a dominant firm that excludes rivals, can engage the Competition Act. The Competition Bureau has published enforcement guidelines on the intellectual property interface. Our insight on IP licensing agreements covers drafting points in detail.

Quebec language rules and brands

Businesses selling in Quebec must reconcile their brands with the Charter of the French Language. Product inscriptions, packaging, catalogues, websites, commercial publications and public signage must generally be in French, with exceptions and conditions for recognized trademarks. Amendments made in 2022 tightened several of these rules, including requirements on the prominence of French on outdoor signage and limits on the use of trademarks in another language where descriptive or generic terms are included. Brand owners entering Quebec should review their marks, packaging and signage early, consider registering French versions of key marks and plan for the costs of compliance. See our French language charter page.

Intellectual property and artificial intelligence

Artificial intelligence raises unresolved IP questions in Canada. The Copyright Act has not been amended to address whether training models on copyrighted works requires authorization, whether outputs generated with limited human input are protected, or who owns them. The federal government has consulted on these issues but, as of November 2026, has not legislated. Patent law raises parallel questions about inventorship and the patentability of AI-assisted inventions.

Until the law is clarified, businesses should manage the risk through contracts with AI vendors and customers, documentation of human creative contributions, review of training data sources and internal policies on the use of generative tools. Our artificial intelligence law page and our insight on AI-generated works and copyright explore these questions.

International protection and cross-border portfolios

Canadian rights are territorial, so a business selling in several countries needs a coordinated filing strategy. Canada participates in the main international systems: the Patent Cooperation Treaty for patents, the Madrid Protocol for trademarks, the Hague Agreement for industrial designs and the Berne Convention for copyright. These systems allow a single international application or a priority claim to support filings in many countries, but each national office, including CIPO, examines and grants rights under its own law and deadlines.

For foreign companies entering Canada, the key decisions are which inventions justify Canadian patent protection given the size of the market and competitors' activities, which brands to register in Canada before launch, and whether French versions of marks are needed for Quebec. For Canadian companies expanding abroad, the questions run the other way, and early decisions about priority deadlines often determine whether protection is available at all. Coordinating with registered agents in each jurisdiction, and keeping a single portfolio record, avoids missed deadlines and inconsistent positions in prosecution and litigation. It also makes diligence far easier when the business later raises capital or is sold.

Intellectual property strategy for businesses

An effective intellectual property strategy aligns protection with the business model. Core steps include:

  1. Audit: identify the assets that create value, from patents and brands to software, data and know-how, and confirm who owns them.
  2. Protect: file patents before public disclosure, register key trademarks in Canada and other markets, and use confidentiality controls for know-how that is better kept secret.
  3. Clear: search for conflicting trademarks and assess freedom to operate before launching products or brands.
  4. Contract: use assignments, licences, confidentiality agreements and joint development terms that allocate ownership, improvements and enforcement rights clearly.
  5. Monitor and enforce: watch for infringing marks, products and online uses, and act proportionately, from demand letters to litigation.
  6. Commercialize: license, franchise or partner on terms that protect the core assets and comply with competition law.

IP is also central to transactions. Buyers and investors in Canadian businesses should diligence ownership, registrations and their status, licences in and out, open-source use, litigation and freedom-to-operate risks. Under the Investment Canada Act, the net benefit assessment can take account of IP, including government-funded intellectual property, and national security reviews may consider sensitive technology. See our page on the Investment Canada Act and our insight on IP strategy for start-ups.

Illustration: a hypothetical German medical device company plans to launch a new product line in Canada through a Canadian subsidiary. Its intellectual property plan should cover Canadian patent filings or national phase entries within the applicable deadlines, claims drafted with the method-of-treatment exclusion in mind, trademark clearance and registration including French-language considerations for Quebec, assignment terms for Canadian engineers and contractors, and a distribution agreement that protects its marks and confidential information.

How TRW & Co helps

We advise Canadian and international businesses and investors on intellectual property in Canada: IP strategy and audits, ownership and assignment structures, licensing and technology transfer, trademark clearance and brand protection including Quebec language issues, copyright and trade secret protection, IP diligence in transactions, and coordination of patent, trademark and copyright litigation. Filing and prosecution before CIPO is handled by registered patent and trademark agents, and Canadian court proceedings by Canadian-licensed litigators, with whom we work closely. This page is general information, not legal advice. To discuss your IP portfolio or a dispute, please contact us.

Frequently asked questions

How long does a patent last in Canada?

For applications filed on or after 1 October 1989, a Canadian patent lasts 20 years from the filing date, subject to maintenance fees (s. 44 of the Patent Act). For applications filed on or after 1 December 2020, an additional term may be granted to compensate for unreasonable delays by CIPO in issuing the patent, if the patentee applies within the prescribed time.

Do I need to use a trademark before registering it in Canada?

No. Since 2019, use is not required before registration. However, three years after registration, anyone can ask the Registrar to require the owner to show use in Canada during the previous three years, and a registration not supported by use or special circumstances may be expunged under s. 45 of the Trademarks Act.

Who owns IP created by employees and contractors?

For copyright, the employer owns works made by an employee in the course of employment unless agreed otherwise, but contractors keep copyright unless they assign it in writing. Patent ownership depends on the circumstances and agreements. Written assignments and moral rights waivers are therefore essential, especially for contractors and founders.

Are methods of medical treatment patentable in Canada?

No. In Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, the Supreme Court of Canada confirmed that methods of medical treatment are not patentable subject matter. Pharmaceutical and medical device applicants should draft claims accordingly, focusing on products, compositions and other forms of claims that remain available.

Where are IP disputes litigated in Canada?

The Federal Court has jurisdiction across Canada over patents, trademarks, copyright and industrial designs, and only it can invalidate a patent or expunge a registration with effect against everyone. Provincial superior courts can also hear infringement claims, particularly when combined with contract or other provincial claims such as breach of confidence.

Sources

  1. Patent Act (R.S.C. 1985, c. P-4)
  2. Trademarks Act (R.S.C. 1985, c. T-13)
  3. Copyright Act (R.S.C. 1985, c. C-42)
  4. Industrial Design Act (R.S.C. 1985, c. I-9)
  5. Criminal Code, s. 391 (R.S.C. 1985, c. C-46)
  6. Supreme Court of Canada: Pharmascience Inc. v. Janssen Inc., 2026 SCC 26 (Case in Brief)

General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.